James E. Ward
- Hematology top 5%
- Multiple Myeloma Research and Treatments 4
- Geriatrics and Gerontology top 5%
- Oncology top 10%
- Global Cancer Incidence and Screening 2
- Colorectal Cancer Screening and Detection 2
- Colorectal Cancer Treatments and Studies 2
- Cancer Immunotherapy and Biomarkers 2
- HER2/EGFR in Cancer Research 2
-
- Protein Degradation and Inhibitors 3
-
- Immunotherapy and Immune Responses 2
- Co-authors
- Keith NaylorBlasé N. PoliteDouglas G. McNeelWalter M. StadlerKenshi SuzukiHans SalwenderJeremy A. RossElizabeth A. Punnoose
- Journals
- Journal of Clinical Oncology (3 papers)Blood (2 papers)Expert Opinion on Biological Therapy (1 paper)
- Partner nations
- United StatesUnited KingdomJapan
In The Last Decade
James E. Ward
16 papers receiving 708 citations
Hit Papers
Peers
Comparison fields: 5 of 80
- Hematology 269
- Geriatrics and Gerontology 53
- Oncology 360
- Genetics 58
- Molecular Biology 340
Countries citing papers authored by James E. Ward
This map shows the geographic impact of James E. Ward's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Ward with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Ward more than expected).
Fields of papers citing papers by James E. Ward
This network shows the impact of papers produced by James E. Ward. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Ward. The network helps show where James E. Ward may publish in the future.
Co-authorship network
The 25 scholars most cited alongside James E. Ward, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 16 | |
| 2 | 2023 | 13 | |
| 3 | Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trialbreakdown → | 2020 | 256 |
| 4 | 2020 | 6 | |
| 5 | 2019 | 28 | |
| 6 | 2019 | 27 | |
| 7 | Systemic Therapy for Early-Stage Breast Cancer: What the Plastic Surgeon Should Know. | 2017 | 6 |
| 8 | 2016 | 43 | |
| 9 | 2016 | 3 | |
| 10 | 2012 | 124 | |
| 11 | 2012 | 1 | |
| 12 | 2010 | 39 | |
| 13 | 2007 | 41 | |
| 14 | 2004 | 27 | |
| 15 | 2003 | 86 | |
| 16 | Colesevelam hydrochloride: Synthesis and testing of a novel polymer gel pharmaceutical. | 2000 | 14 |
About James E. Ward
James E. Ward is a scholar working on Hematology, Oncology, Radiological and Ultrasound Technology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 16 papers that have together received 730 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (4 papers), Protein Degradation and Inhibitors (3 papers), Global Cancer Incidence and Screening (2 papers), Colorectal Cancer Screening and Detection (2 papers), Colorectal Cancer Treatments and Studies (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Immunotherapy and Immune Responses (2 papers) and HER2/EGFR in Cancer Research (2 papers). The work is most often cited by research in Hematology (269 citations), Geriatrics and Gerontology (53 citations), Oncology (360 citations), Genetics (58 citations) and Molecular Biology (340 citations). James E. Ward has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Keith Naylor, Blasé N. Polite, Douglas G. McNeel, Walter M. Stadler, Kenshi Suzuki, Hans Salwender, Jeremy A. Ross, Elizabeth A. Punnoose, Rakesh Popat and Shaji Kumar. Their work appears in journals such as Journal of Clinical Oncology, Blood, Expert Opinion on Biological Therapy, The Lancet Oncology and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.